Intracranial Genetically Modified Immune Cells (TGFβR2KO/IL13Rα2 CAR T-Cells) for the Treatment of Recurrent or Progressive Glioblastoma or Grade 3 or 4 IDH-Mutant Astrocytoma

NCT06815029 · clinicaltrials.gov ↗

PHASE1

Phase

RECRUITING

Status

27

Enrollment

OTHER

Sponsor class

Conditions

Recurrent Astrocytoma, IDH-Mutant, Grade 3
Recurrent Astrocytoma, IDH-Mutant, Grade 4
Recurrent Glioblastoma

Interventions

PROCEDURE: Biospecimen Collection
BIOLOGICAL: Chimeric Antigen Receptor T-Cell Therapy
PROCEDURE: Echocardiography
OTHER: Fludeoxyglucose F-18
PROCEDURE: Intracranial Catheter Placement
PROCEDURE: Leukapheresis
PROCEDURE: Magnetic Resonance Imaging
PROCEDURE: Positron Emission Tomography
PROCEDURE: Resection

Sponsor

City of Hope Medical Center

Collaborators

[object Object]